Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma

Rationale: Hepatocellular carcinoma (HCC) is an aggressive malignant solid tumor wherein CDK1/PDK1/β-Catenin is activated, suggesting that inhibition of this pathway may have therapeutic potential. Methods: CDK1 overexpression and clinicopathological parameters were analyzed. HCC patient-derived xen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chuan Xing, Wang, Xiao Qi, Chok, Siu Ho, Man, Kwan, Tsang, Simon Hing Yin, Chan, Albert Chi Yan, Ma, Ka Wing, Xia, Wei, Cheung, Tan To
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071527/
https://www.ncbi.nlm.nih.gov/pubmed/30083256
http://dx.doi.org/10.7150/thno.25487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071527/
https://www.ncbi.nlm.nih.gov/pubmed/30083256
http://dx.doi.org/10.7150/thno.25487

Ejemplares similares